类风湿关节炎合并恶性淋巴瘤与其他恶性肿瘤的比较:基于日本全国风湿病数据库的分析
基于日本全国风湿病数据库2012至2018年935例新发恶性肿瘤的类风湿关节炎患者,15.5%为恶性淋巴瘤,与肺癌14.3%相近。多因素分析显示,甲氨蝶呤使用(OR 2.22,95%CI 1.32-3.73,p=0.003)和非甾体抗炎药使用(OR 2.51,95%CI 1.58-3.98,p<0.001)与发生恶性淋巴瘤而非其他恶性肿瘤显著相关,生物改善病情抗风湿药未见此关联。恶性肿瘤发生后,恶性淋巴瘤组甲氨蝶呤使用率为0%,其他恶性肿瘤组为41.8%,两组治疗格局差异明显。
要点
- 935例类风湿关节炎新发恶性肿瘤患者中15.5%为恶性淋巴瘤,与肺癌14.3%相近。
- 甲氨蝶呤使用(OR 2.22,95%CI 1.32-3.73,p=0.003)和非甾体抗炎药使用(OR 2.51,95%CI 1.58-3.98,p<0.001)与恶性淋巴瘤发生显著相关。
- 恶性肿瘤发生后1年,恶性淋巴瘤组甲氨蝶呤使用率为0%,其他恶性肿瘤组为41.8%。
核心结论
- 长期接受甲氨蝶呤和非甾体抗炎药治疗的患者发生恶性淋巴瘤的风险可能相对较高。
- 恶性淋巴瘤与其他恶性肿瘤患者发生恶性肿瘤后的治疗格局差异很大,应建立不同的治疗策略。
研究设计与样本
- 研究基于日本全国风湿病数据库2012至2018年登记的110571人年数据,识别出935例新发恶性肿瘤的类风湿关节炎患者。
- 分析队列1和分析队列2分别纳入597例和490例在恶性肿瘤发生前1年和发生后1年有可用数据的患者。
- 采用多因素logistic回归分析纵向评估与恶性淋巴瘤发生相关的因素。
主要发现
- 935例患者平均年龄70.5岁(标准差9.9),其中15.5%为恶性淋巴瘤,肺癌为14.3%。
- 队列1中,恶性肿瘤发生前1年,恶性淋巴瘤组甲氨蝶呤、生物改善病情抗风湿药和非甾体抗炎药使用率分别为74.4%、23.4%和56.7%,其他恶性肿瘤组分别为56.8%、25.4%和35.3%。
- 两组临床疾病活动指数和C反应蛋白相似。
- 多因素分析显示,甲氨蝶呤使用(OR 2.22,95%CI 1.32-3.73,p=0.003)和非甾体抗炎药使用(OR 2.51,95%CI 1.58-3.98,p<0.001)与发生恶性淋巴瘤而非其他恶性肿瘤显著相关,生物改善病情抗风湿药未见此关联。
- 队列2中,恶性肿瘤发生后1年,恶性淋巴瘤组甲氨蝶呤使用率为0%,其他恶性肿瘤组为41.8%;两组约15%使用生物改善病情抗风湿药、50%使用糖皮质激素;恶性淋巴瘤组更优先处方IL-6抑制剂;第1年临床疾病活动指数缓解率在恶性淋巴瘤组和其他恶性肿瘤组分别为37.3%和31.1%。
临床怎么用
- 作者认为,长期使用甲氨蝶呤和非甾体抗炎药的患者发生恶性淋巴瘤的风险可能相对较高。
- 作者认为,恶性淋巴瘤与其他恶性肿瘤患者发生恶性肿瘤后的治疗格局差异很大,应建立不同的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The background status and the current treatment options of patients with rheumatoid arthritis (RA) who develop malignant lymphoma (ML) and other malignancies are unclear. This study investigated the differences in background factors between ML and other malignancies that occur in RA patients and post-malignancy treatment. METHODS: We identified 935 RA patients with new-onset malignancies among 110,571 person-years registered in the National Database of Rheumatic Disease in Japan from 2012 to 2018. Analysis cohorts 1 and 2 included 597 and 490 patients with available data for 1 year before and after the development of malignancies, respectively. Factors associated with the development of ML were longitudinally evaluated by multiple logistic regression analyses. RESULTS: Of the 935 patients (mean age 70.5, standard deviation 9.9), 15.5% had ML; this was comparable to the rate of lung cancer (14.3%). In cohort 1, methotrexate (MTX), biological disease-modifying anti-rheumatic drugs (bDMARDs), and non-steroidal anti-inflammatory drugs (NSAIDs) were used in 74.4%, 23.4%, and 56.7% of ML and in 56.8%, 25.4%, and 35.3% of other malignancies 1 year before the occurrence of malignancies. Clinical disease activity index (CDAI) and C-reactive protein were similar between the two groups. Multivariable analysis showed that MTX use (odds ratio [OR]: 2.22, 95% CI [confidence interval]: 1.32-3.73, p=0.003) and NSAID use (OR: 2.51, 95% CI: 1.58-3.98, p <0.001) were significantly associated with the development of ML versus other malignancies. However, this association was not observed with bDMARDs. In cohort 2, one year after the development of malignancies, MTX was used in none of ML and 41.8% of patients who developed other malignancies. In both malignancy groups, approximately 15% of patients received bDMARDs and 50% received glucocorticoids. IL-6 inhibitors were preferentially prescribed in patients with ML versus those with other malignancies. At year 1, CDAI remission was achieved in 37.3% and 31.1% of patients in the ML and other malignancy groups, respectively. CONCLUSION: Patients receiving long-term treatment with MTX and NSAIDs may be at a relatively high risk of developing ML. The treatment landscape after developing malignancies differed considerably between patients with ML and other malignancies, and different treatment strategies should be established.
引用
- Mizushima M, Sugihara T, Matsui T, et al. Comparison between rheumatoid arthritis with malignant lymphoma and other malignancies: Analysis of a National Database of Rheumatic Disease in Japan. Semin Arthritis Rheum. 2023. PMID: 37939601. doi:10.1016/j.semarthrit.2023.152301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。